HAE

Haemonetics Corporation NYSE

Healthcare ·Medical - Instruments & Supplies ·US · haemonetics.com

$59.26

Mkt Cap $3.0B

52w Low $47.32 29.8% of range 52w High $87.32

50d MA $60.06 200d MA $63.69

P/E (TTM) 17.9x

EV/EBITDA 11.5x

P/B 3.6x

Debt/Equity 1.5x

ROE 19.2%

P/FCF 22.3x

RSI (14) —

ATR (14) —

Beta 0.36

50d MA $60.06

200d MA $63.69

Avg Volume 823.0K

About

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technolog…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 5, 2026	AMC	1.27	1.31	+3.1%	65.02	+0.3%	-8.7%	-11.3%	-8.6%	-11.6%	-11.4%	-1.2%	—
Nov 6, 2025	AMC	1.12	1.27	+13.4%	67.11	+0.3%	+1.9%	+5.0%	+6.9%	+9.0%	+10.1%	+24.0%	—
Aug 7, 2025	AMC	1.01	1.10	+8.9%	55.63	-0.7%	-2.9%	-5.7%	-6.1%	-3.1%	-5.9%	-2.8%	—
May 8, 2025	AMC	1.22	1.24	+1.6%	68.01	-0.4%	+0.3%	+3.3%	+1.7%	+0.9%	+2.0%	+5.4%	—
Feb 6, 2025	AMC	1.18	1.19	+0.8%	62.99	-1.7%	-5.8%	-3.7%	-2.3%	-2.7%	-1.1%	+7.1%	—
Nov 7, 2024	AMC	1.09	1.12	+2.8%	86.53	+0.9%	+1.0%	+5.6%	+7.9%	+6.1%	+4.9%	-4.1%	—
Aug 8, 2024	AMC	1.03	1.02	-1.0%	76.43	+1.2%	+0.8%	-2.3%	-2.8%	-4.3%	-3.2%	-4.8%	—
May 9, 2024	AMC	0.88	0.90	+2.3%	92.60	+1.8%	+3.5%	+3.9%	+5.2%	+4.2%	+2.4%	-7.3%	—
Feb 8, 2024	AMC	0.97	1.04	+7.2%	78.11	-0.3%	-5.0%	-4.3%	-8.2%	-8.8%	-8.0%	+0.3%	—
Nov 2, 2023	AMC	0.94	0.99	+5.3%	85.46	+2.7%	+3.5%	+3.5%	+3.6%	+0.8%	+0.1%	-2.5%	—
Aug 8, 2023	AMC	0.73	1.05	+43.8%	89.94	+1.4%	+0.5%	+1.1%	+1.5%	+3.2%	+3.2%	-2.3%	—
May 11, 2023	AMC	0.68	0.77	+13.2%	85.84	+1.4%	+4.2%	+3.9%	+3.9%	-0.3%	-2.9%	+2.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 13	Mizuho	Maintains	Outperform → Outperform	—	$57.32	$57.28	-0.1%	+3.4%	+5.5%	+8.1%	+4.9%	+7.5%
Mar 11	Citigroup	Maintains	Neutral → Neutral	—	$62.85	$62.37	-0.8%	-3.5%	-5.3%	-4.7%	-5.0%	-4.5%
Feb 6	BTIG	Maintains	Buy → Buy	—	$65.02	$65.19	+0.3%	-8.7%	-11.3%	-8.6%	-11.6%	-11.4%
Feb 6	Citigroup	Maintains	Neutral → Neutral	—	$65.02	$65.19	+0.3%	-8.7%	-11.3%	-8.6%	-11.6%	-11.4%
Feb 6	Barrington Research	Maintains	Outperform → Outperform	—	$65.02	$65.19	+0.3%	-8.7%	-11.3%	-8.6%	-11.6%	-11.4%
Feb 6	Mizuho	Maintains	Outperform → Outperform	—	$65.02	$65.19	+0.3%	-8.7%	-11.3%	-8.6%	-11.6%	-11.4%
Feb 2	Barrington Research	Maintains	Outperform → Outperform	—	$66.66	$66.73	+0.1%	-1.3%	-2.7%	-1.1%	-2.5%	-11.0%
Jan 12	Barrington Research	Maintains	Outperform → Outperform	—	$82.03	$82.34	+0.4%	+1.1%	-3.9%	-7.7%	-9.8%	-12.0%
Jan 9	BTIG	Maintains	Buy → Buy	—	$84.04	$84.13	+0.1%	-2.4%	-1.3%	-6.2%	-9.9%	-11.9%
Dec 17	Mizuho	Maintains	Outperform → Outperform	—	$81.11	$80.80	-0.4%	-1.4%	-1.5%	-1.1%	-0.9%	-0.9%
Dec 15	Baird	Maintains	Outperform → Outperform	—	$83.49	$82.32	-1.4%	-3.7%	-2.9%	-4.2%	-4.3%	-3.9%
Dec 15	Needham	Downgrade	Buy → Hold	—	$83.49	$82.32	-1.4%	-3.7%	-2.9%	-4.2%	-4.3%	-3.9%
Dec 12	JP Morgan	Maintains	Neutral → Neutral	—	$84.45	$83.84	-0.7%	-1.1%	-4.8%	-4.0%	-5.3%	-5.4%
Dec 11	Citigroup	Downgrade	Buy → Neutral	—	$87.16	$85.86	-1.5%	-3.1%	-4.2%	-7.8%	-6.9%	-8.2%
Nov 21	BTIG	Maintains	Buy → Buy	—	$75.12	$75.73	+0.8%	+4.9%	+6.0%	+7.3%	+7.5%	+8.3%
Nov 7	Barrington Research	Maintains	Outperform → Outperform	—	$67.11	$67.31	+0.3%	+1.9%	+5.0%	+6.9%	+9.0%	+10.1%
Nov 7	Needham	Maintains	Buy → Buy	—	$67.11	$67.31	+0.3%	+1.9%	+5.0%	+6.9%	+9.0%	+10.1%
Nov 6	BTIG	Maintains	Buy → Buy	—	$50.72	$56.88	+12.1%	+32.3%	+34.8%	+39.0%	+41.4%	+44.2%
Oct 21	Barrington Research	Maintains	Outperform → Outperform	—	$50.71	$50.58	-0.3%	+0.9%	+1.2%	+1.3%	+1.1%	+1.0%
Oct 7	Citigroup	Maintains	Buy → Buy	—	$49.55	$49.46	-0.2%	-0.6%	+2.9%	+1.2%	-1.4%	+1.4%
Sep 23	Barrington Research	Maintains	Outperform → Outperform	—	$51.18	$51.11	-0.1%	-1.0%	-1.1%	-6.9%	-5.9%	-6.0%
Aug 11	Raymond James	Downgrade	Strong Buy → Outperform	—	$53.99	$53.80	-0.4%	-2.8%	-3.3%	-0.2%	-3.1%	-0.5%
Aug 8	Mizuho	Maintains	Outperform → Outperform	—	$55.63	$55.25	-0.7%	-2.9%	-5.7%	-6.1%	-3.1%	-5.9%
Aug 8	JP Morgan	Downgrade	Overweight → Neutral	—	$55.63	$55.25	-0.7%	-2.9%	-5.7%	-6.1%	-3.1%	-5.9%
Aug 8	Barrington Research	Maintains	Outperform → Outperform	—	$55.63	$55.25	-0.7%	-2.9%	-5.7%	-6.1%	-3.1%	-5.9%
Aug 7	Needham	Maintains	Buy → Buy	—	$75.77	$72.08	-4.9%	-26.6%	-28.7%	-30.8%	-31.1%	-28.9%
Jul 11	Barrington Research	Maintains	Outperform → Outperform	—	$78.17	$77.66	-0.7%	-3.4%	-1.9%	-4.5%	-4.8%	-6.0%
Jul 9	Citigroup	Upgrade	Neutral → Buy	—	$75.97	$77.86	+2.5%	+2.0%	+2.9%	-0.6%	+0.9%	-1.8%
May 20	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$69.36	$68.86	-0.7%	-0.6%	-3.5%	-4.6%	-4.8%	-2.0%
May 9	Raymond James	Maintains	Strong Buy → Strong Buy	—	$68.01	$67.75	-0.4%	+0.3%	+3.3%	+1.7%	+0.9%	+2.0%
May 8	Needham	Maintains	Buy → Buy	—	$64.25	$66.82	+4.0%	+5.9%	+6.1%	+9.3%	+7.6%	+6.8%
Feb 7	Barrington Research	Maintains	Outperform → Outperform	—	$62.99	$61.93	-1.7%	-5.8%	-3.7%	-2.3%	-2.7%	-1.1%
Feb 7	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$62.99	$61.93	-1.7%	-5.8%	-3.7%	-2.3%	-2.7%	-1.1%
Feb 7	Raymond James	Maintains	Strong Buy → Strong Buy	—	$62.99	$61.93	-1.7%	-5.8%	-3.7%	-2.3%	-2.7%	-1.1%
Feb 7	Needham	Maintains	Buy → Buy	—	$62.99	$61.93	-1.7%	-5.8%	-3.7%	-2.3%	-2.7%	-1.1%
Dec 4	Barrington Research	Maintains	Outperform → Outperform	—	$85.26	$85.58	+0.4%	-2.1%	-5.4%	-4.8%	-2.7%	-1.6%
Dec 3	Needham	Maintains	Buy → Buy	—	$87.48	$88.03	+0.6%	-2.5%	-4.5%	-7.8%	-7.2%	-5.2%
Nov 15	Needham	Maintains	Buy → Buy	—	$90.75	$91.37	+0.7%	-1.7%	-2.8%	-6.5%	-6.4%	-5.9%
Nov 8	Raymond James	Upgrade	Outperform → Strong Buy	—	$86.53	$87.27	+0.9%	+1.0%	+5.6%	+7.9%	+6.1%	+4.9%
Nov 8	Barrington Research	Maintains	Outperform → Outperform	—	$86.53	$87.27	+0.9%	+1.0%	+5.6%	+7.9%	+6.1%	+4.9%
Sep 23	Barrington Research	Maintains	Outperform → Outperform	—	$74.83	$75.13	+0.4%	+2.1%	+0.9%	+0.3%	+2.3%	+6.6%
Aug 22	Citigroup	Maintains	Neutral → Neutral	—	$75.41	$75.50	+0.1%	+0.1%	+1.1%	+1.4%	+1.7%	-0.4%
Aug 13	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$74.66	$75.00	+0.5%	-0.5%	-2.0%	-0.9%	+0.9%	+0.3%
Aug 9	Barrington Research	Maintains	Outperform → Outperform	—	$76.43	$77.33	+1.2%	+0.8%	-2.3%	-2.8%	-4.3%	-3.2%
Jun 12	Needham	Upgrade	Hold → Buy	—	$83.41	$86.34	+3.5%	+3.0%	+3.2%	+1.5%	+2.6%	+2.4%
May 10	Barrington Research	Maintains	Outperform → Outperform	—	$92.60	$94.24	+1.8%	+3.5%	+3.9%	+5.2%	+4.2%	+2.4%
May 10	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$92.60	$94.24	+1.8%	+3.5%	+3.9%	+5.2%	+4.2%	+2.4%
Apr 12	Barrington Research	Maintains	Outperform → Outperform	—	$86.52	$85.98	-0.6%	-1.5%	-1.9%	-2.7%	-1.9%	-3.5%
Feb 13	Barrington Research	Maintains	Outperform → Outperform	—	$74.77	$73.18	-2.1%	-4.1%	-4.7%	-3.9%	-3.2%	-4.5%
Nov 3	Barrington Research	Maintains	Outperform → Outperform	—	$85.46	$87.78	+2.7%	+3.5%	+3.5%	+3.6%	+0.8%	+0.1%

Recent Filings

8-K · 7.01 ! Medium

Haemonetics Corporation -- 8-K 7.01: Regulation FD Disclosure

Haemonetics repaid $300 million in convertible notes at maturity, eliminating this debt obligation and reducing its leverage.

Mar 3

8-K · 7.01 ! Medium

Haemonetics Corporation -- 8-K 7.01: Regulation FD Disclosure

Haemonetics published its 2024-2025 Corporate Responsibility Report, providing transparency on environmental, social, and governance practices that may influence investor decisions on corporate accountability.

Feb 12

8-K

Haemonetics Corporation -- 8-K Filing

Haemonetics' Q3 results demonstrate strong organic growth and margin expansion in core operations, excluding transitional CSL Plasma sales, indicating resilient underlying business performance despite portfolio changes.

Feb 5

Data updated apr 25, 2026 12:52pm · Source: massive.com